Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Cytomegalovirus Infection After Transplantation: a Study of New Markers to Optimize the Selection of Antiviral Therapies and Reduce the Risk of Developing Direct and Indirect Infection-related Complications (CMV-TX-2025)

12 november 2026 bijgewerkt door: IRCCS Azienda Ospedaliero-Universitaria di Bologna

Background and Rationale Cytomegalovirus (CMV) remains a major cause of morbidity and mortality in recipients of solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT). Current management relies on antiviral prophylaxis or pre-emptive therapy guided primarily by CMV-DNAemia monitoring. However, recently introduced antivirals such as letermovir and maribavir have changed the virological profile of CMV infection, highlighting limitations of DNAemia as a marker of active viral replication and increasing the need for improved resistance monitoring.

Preliminary studies suggest that CMV-RNAemia (UL21.5 mRNA) may be a more accurate marker of active viral replication and may detect viral clearance approximately 7-14 days earlier than CMV-DNAemia. In parallel, Next Generation Sequencing (NGS) may provide superior detection of antiviral resistance mutations, including low-frequency variants that cannot be identified by conventional Sanger sequencing.

Primary Objective To determine whether using CMV-RNAemia to guide discontinuation of antiviral therapy in transplant recipients can reduce treatment duration and drug-related toxicity without increasing the risk of CMV relapse, compared with the current standard based on CMV-DNAemia.

Secondary Objectives

Compare the diagnostic performance of NGS and Sanger sequencing in detecting CMV antiviral resistance mutations.

Estimate the incidence of resistant or refractory CMV infection (R/R-CMV) in transplant recipients.

Identify risk factors associated with the development of R/R-CMV according to transplant type.

Study Design This is a single-center, pragmatic, randomized controlled interventional study conducted at the IRCCS Azienda Ospedaliero-Universitaria di Bologna.

Adult transplant recipients (≥18 years) with CMV infection requiring antiviral therapy will be randomized (1:1) into two groups:

Experimental arm: antiviral therapy discontinued after two consecutive negative CMV-RNAemia results.

Control arm: antiviral therapy discontinued after two consecutive negative CMV-DNAemia results.

Patients will be followed from treatment initiation, with virological monitoring continuing during therapy and follow-up.

Population and Sample Size The study plans to enroll approximately 330 CMV infection episodes, including an estimated 10% drop-out rate, with 150 participants per study arm plus additional cases to compensate for losses.

Endpoints Primary endpoints include:

Time to treatment discontinuation. Time to viral clearance. Incidence and timing of clinically significant CMV relapse. Antiviral drug toxicity.

Secondary endpoints include:

Sensitivity, specificity, and predictive value of NGS versus Sanger sequencing. Incidence of resistant/refractory CMV infection. Identification of clinical and virological risk factors for resistance.

Resistance Analysis In suspected resistant or refractory CMV infections, residual biological samples will undergo NGS analysis targeting CMV genes involved in antiviral resistance (UL97, UL54, UL56, UL89, UL27, UL51). Results will be compared with standard Sanger sequencing to assess earlier detection of resistance mutations and minor viral variants.

Expected Impact The study aims to establish CMV-RNAemia as a clinically useful marker for earlier identification of viral clearance, enabling shorter antiviral treatment and reduced toxicity. It also seeks to validate NGS-based resistance testing as a more sensitive tool for detecting emerging CMV drug resistance, ultimately supporting a more personalized approach to CMV management in transplant recipients and potentially other immunocompromised populations.

Study Duration and Funding The study is expected to last 24 months (18 months recruitment, 4 months follow-up, 2 months analysis) and is funded by the Italian Ministry of Health (Ricerca Corrente 2026, project RC-2026-2802099).

Studie Overzicht

Toestand

Nog niet aan het werven

Studietype

Ingrijpend

Inschrijving (Geschat)

330

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

    • Italy
      • Bologna, Italy, Italië, 40138
        • IRCCS Azienda Ospedaliero-Universitaria di Bologna

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • CSE/SOT transplant patient;
  • Currently receiving antiviral medication;
  • Age ≥ 18 years
  • Signed informed consent form for participation and data processing

Exclusion Criteria:

  • Localized CMV infection / organ disease.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Antiviral therapy will be discontinued after two consecutive negative results for CMV-RNAemia

From enrollment (time 0, t0) until viral clearance is achieved (tn), all remaining biological material from blood samples analyzed for the monitoring/diagnosis of CMV infection will be collected and stored. Plasma samples will be analyzed for the presence of UL21.5 mRNA (CMV-RNAemia UL21.5) using the automated CMV-RNA ELITe MGB kit on an InGenius instrument (ELITech Group).

During the treatment period and the follow-up period, patients will be monitored in accordance with current clinical practice through serial virologic assessments (CMV-DNAemia) and the collection of relevant clinical data. Assessments will be conducted weekly during the first three months after transplantation, every 15 days from the fourth to the sixth month, and then monthly from the seventh to the twelfth month. For the purposes of evaluating the primary endpoint, the first four months of follow-up will be taken into account.

Actieve vergelijker: Antiviral therapy will be discontinued after two consecutive negative results for CMV-DNAemia

During the treatment period and the follow-up period, patients will be monitored in accordance with current clinical practice through serial virologic assessments (CMV-DNAemia) and the collection of relevant clinical data. Assessments will be conducted weekly during the first three months after transplantation, every 15 days from the fourth to the sixth month, and then monthly from the seventh to the twelfth month. For the purposes of evaluating the primary endpoint, the first four months of follow-up will be taken into account.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
CMV-DNAemia VS CMV-DNAemia 1
Tijdsspanne: Periprocedural

To determine whether the use of CMV-RNAemia to guide the discontinuation of antiviral therapy in transplant recipients (SOT and CSE) results in a reduction in the duration of treatment exposure compared to the standard strategy based on CMV-DNAemia, and a possible reduction in toxicity from anti-CMV drugs, without increasing the risk of recurrence of the infection.

Measure: Time to discontinuation of therapy

Periprocedural
CMV-DNAemia VS CMV-DNAemia 2
Tijdsspanne: Periprocedural

To determine whether the use of CMV-RNAemia to guide the discontinuation of antiviral therapy in transplant recipients (SOT and CSE) results in a reduction in the duration of treatment exposure compared to the standard strategy based on CMV-DNAemia, and a possible reduction in toxicity from anti-CMV drugs, without increasing the risk of recurrence of the infection.

Measure: Time to viral clearance

Periprocedural
CMV-DNAemia VS CMV-DNAemia 3
Tijdsspanne: Follow-up analysis (up to 4 months)

To determine whether the use of CMV-RNAemia to guide the discontinuation of antiviral therapy in transplant recipients (SOT and CSE) results in a reduction in the duration of treatment exposure compared to the standard strategy based on CMV-DNAemia, and a possible reduction in toxicity from anti-CMV drugs, without increasing the risk of recurrence of the infection.

Measure: Incidence and time to recurrence of clinically significant CMV infection

Follow-up analysis (up to 4 months)
CMV-DNAemia VS CMV-DNAemia 4
Tijdsspanne: Periprocedural

To determine whether the use of CMV-RNAemia to guide the discontinuation of antiviral therapy in transplant recipients (SOT and CSE) results in a reduction in the duration of treatment exposure compared to the standard strategy based on CMV-DNAemia, and a possible reduction in toxicity from anti-CMV drugs, without increasing the risk of recurrence of the infection.

Measure: Toxicity associated with anti-CMV drugs

Periprocedural

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Sanger sequencing VS NGS sequencing 1
Tijdsspanne: Follow up analysis (up to 1 year)

Evaluate the diagnostic performance of NGS sequencing compared to the Sanger method in identifying CMV mutations associated with drug resistance, including minor variants.

Measure: Sensitivity and specificity of NGS compared to Sanger

Follow up analysis (up to 1 year)
Incidence of refractory CMV infection
Tijdsspanne: Follow up analysis (up to 1 year)

To estimate the incidence of resistant or refractory CMV infection (R/R CMV) in transplant recipients (SOT and CSE).

Measure: Incidence of resistant or refractory CMV infection

Follow up analysis (up to 1 year)
Risk factors for refractory CMV infection
Tijdsspanne: Follow up analysis (up to 1 year)

To compare the risk factors associated with the development of resistant or refractory CMV infection (R/R CMV) by type of transplant.

Measure: Risk factors associated with resistant or refractory CMV infection

Follow up analysis (up to 1 year)
Sanger sequencing VS NGS sequencing 2
Tijdsspanne: Follow up analysis (up to 1 year)

Evaluate the diagnostic performance of NGS sequencing compared to the Sanger method in identifying CMV mutations associated with drug resistance, including minor variants.

Measure: Predictive value of NGS compared to Sanger

Follow up analysis (up to 1 year)
Sanger sequencing VS NGS sequencing 3
Tijdsspanne: Follow up analysis (up to 1 year)

Evaluate the diagnostic performance of NGS sequencing compared to the Sanger method in identifying CMV mutations associated with drug resistance, including minor variants.

Measure: Time required to identify mutations using NGS compared to Sanger

Follow up analysis (up to 1 year)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 november 2026

Primaire voltooiing (Geschat)

1 juni 2028

Studie voltooiing (Geschat)

1 juni 2028

Studieregistratiedata

Eerst ingediend

5 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

12 november 2026

Eerst geplaatst (Werkelijk)

18 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

18 november 2026

Laatste update ingediend die voldeed aan QC-criteria

12 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Andere studie-ID-nummers

  • CMV-TX-2025
  • WFR 2802099 (Ander subsidie-/financieringsnummer: Italian Ministry of Health)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren